<code id='70C5C7C376'></code><style id='70C5C7C376'></style>
    • <acronym id='70C5C7C376'></acronym>
      <center id='70C5C7C376'><center id='70C5C7C376'><tfoot id='70C5C7C376'></tfoot></center><abbr id='70C5C7C376'><dir id='70C5C7C376'><tfoot id='70C5C7C376'></tfoot><noframes id='70C5C7C376'>

    • <optgroup id='70C5C7C376'><strike id='70C5C7C376'><sup id='70C5C7C376'></sup></strike><code id='70C5C7C376'></code></optgroup>
        1. <b id='70C5C7C376'><label id='70C5C7C376'><select id='70C5C7C376'><dt id='70C5C7C376'><span id='70C5C7C376'></span></dt></select></label></b><u id='70C5C7C376'></u>
          <i id='70C5C7C376'><strike id='70C5C7C376'><tt id='70C5C7C376'><pre id='70C5C7C376'></pre></tt></strike></i>

          Home / Wikipedia / focus

          focus


          focus

          author:focus    Page View:86
          Adobe

          LONDON — GSK said Tuesday it would purchase the asthma-focused drug developer Aiolos Bio for $1 billion upfront, the latest in a string of pharma acquisitions that are bolstering hopes for the industry’s year ahead.

          The deal includes up to another $400 million in payments if certain milestones are met.

          advertisement

          Aiolos was launched just last year, based in both San Francisco and London. The company, which announced a $245 million Series A round in October, has been readying a Phase 2 trial of its candidate AIO-001 in adult asthma.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In